A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01665352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the safety and effect of TTP054 versus placebo on glucose control in patients with type 2 diabetes.
Study identification
- NCT ID
- NCT01665352
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 186 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2012
- Primary completion
- Apr 30, 2013
- Completion
- Apr 30, 2013
- Last update posted
- Feb 9, 2017
2012 – 2013
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 18 | Chula Vista | California | 91911 | — |
| Site 1 | Los Angeles | California | 90057 | — |
| Site 13 | Denver | Colorado | 80220 | — |
| Site 4 | Coral Gables | Florida | 33134 | — |
| Site 5 | Port Orange | Florida | 32127 | — |
| Site 3 | Honolulu | Hawaii | 96814 | — |
| Site 17 | Indianapolis | Indiana | 46254 | — |
| Site 7 | Louisville | Kentucky | 40213 | — |
| Site 8 | Auburn | Maine | 04210 | — |
| Site 9 | Las Vegas | Nevada | 89101 | — |
| Site 26 | Trenton | New Jersey | 08611 | — |
| Site 12 | Rochester | New York | 14609 | — |
| Site 14 | Cincinnati | Ohio | 45219 | — |
| Site 6 | Mt. Pleasant | South Carolina | 29464 | — |
| Site 16 | Dallas | Texas | 75230 | — |
| Site 10 | Houston | Texas | 77072 | — |
| Site 2 | Houston | Texas | 77074 | — |
| Site 11 | Katy | Texas | 77450 | — |
| Site 15 | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01665352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2017 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01665352 live on ClinicalTrials.gov.